Evolve Private Wealth LLC Sells 1,107 Shares of United Therapeutics Corporation $UTHR

Evolve Private Wealth LLC lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 7.9% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 12,913 shares of the biotechnology company’s stock after selling 1,107 shares during the period. Evolve Private Wealth LLC’s holdings in United Therapeutics were worth $7,657,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Torren Management LLC bought a new stake in United Therapeutics during the 4th quarter valued at approximately $26,000. Activest Wealth Management grew its holdings in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its position in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics in the 4th quarter valued at approximately $31,000. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several research reports. Bank of America lifted their price target on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. UBS Group boosted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $619.42.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $549.17, for a total value of $5,491,700.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,366,132.92. The trade was a 34.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $552.40, for a total transaction of $5,247,800.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,379,381.20. The trade was a 19.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 624,968 shares of company stock valued at $353,723,102. 8.60% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

Shares of UTHR opened at $536.59 on Monday. The stock has a market cap of $22.78 billion, a P/E ratio of 19.81, a P/E/G ratio of 1.75 and a beta of 0.57. The business’s 50 day moving average price is $564.47 and its 200-day moving average price is $523.72. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the business earned $6.63 EPS. On average, equities analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.